Building the Future of Targeted Protein Degradation Medicines with Nello Mainolfi

In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities and lessons learned from building a company at the forefront targeted protein degradation.    Episode Timestamps;  00:00 Welcome to Idea Collider  00:18 Kymera 2026 Catalysts  02:33 De Risking with Degraders  02:54 Targeted Protein Degradation 101  06:20 KT-621 STAT6 Degrader 08:16 Rethinking Type 2 Disease Treatment 12:21 Nello’s Path to CEO  16:32 Building a Standalone Biotech  23:19 Partnering with Big Pharma  26:51 Culture and Office Energy  32:03 Capital Plan and Potential Launches 36:24 Belief and Execution Mindset  39:00 Life Outside the Lab  40:07 Where to Follow Kymera  40:35 Closing Thanks    Don't forget to Like, Share, Subscribe, Rate, and Review!      Keep up with Nello Mainolfi & Kymera LinkedIn: https://www.linkedin.com/in/nello-mainolfi-2b55421a/ or https://www.linkedin.com/company/kymeratherapeutics/ Website: https://www.kymeratx.com/      Follow IDEA Pharma On;  Website: https://www.ideapharma.com/  LinkedIn: https://www.linkedin.com/company/idea-pharma/      Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/